Randomized clinical trials in hepatocellular carcinoma and biliary cancer

Surgical Oncology Clinics of North America

Volumn 11, Issue 1, 2002, Pages 193-205

  Martin II, Robert C G ^a   Jarnagin, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINATED POPPYSEED OIL; POLYPRENOIC ACID;

BILE DUCT CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0036136674     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(03)00081-4     Document Type: Review

References (40)

1. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
2. Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study
3. Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil
4. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients
5. Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy
6. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma
7. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma
8. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study
9. A randomized phase II study of acivicin and 4′deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study
10. Unresectable hepatocellular carcinoma: A prospective controlled trial with tamoxifen
11. Drainage is unnecessary after elective liver resection
12. Phase III trial of irradiation plus chemotherapy for patients with hepatic metastases and hepatoma
13. A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization
14. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer
15. Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison
16. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison between L-TAE with farmorubicin and L-TAE with Adriamycin: Preliminary results (second cooperative study)
17. Multicentre study of the treatment of primary liver cancer in Africa with two anthracycline drugs
18. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC)
19. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial
20. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial
21. Adjuvant intra-arterial iodine-131-labelled Lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
22. Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy
23. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: A prospective randomized study
24. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
25. Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study
26. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial
27. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
28. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with Adriamycin
29. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma
30. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
31. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: A prospective randomized study
32. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: An RTOG study
33. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma
34. Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer
35. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma
36. Postoperative chemoimmunotherapy for the treatment of liver cancer
37. Chemohormonal therapy of unresectable hepatocellular carcinoma
38. The effect of gamma-linolenic acid, an in vitro cytostatic substance contained in evening primrose oil, on primary liver cancer. A double-blind placebo controlled trial
39. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal
40. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma